[1] Aithal GP, Watkins PB, Andrade RJ,et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Phamacol Ther, 2011,89:806-815.
[2] 祁亚宾,邱玲,姜红丽,等. 药物性肝损伤394例临床特点分析.临床肝胆病杂志,2014,30:438-441.
[3] Danan G, Benichou C. Causality assessment of adverse reactions to drugs I.A novel method based on the conclusions of international consensus meetings: application to drug induced liver injuries. J Clin Epidemiol. 1993,46:1323-1330
[4] Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: The diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol, 2014, 109: 950-966.
[5] Daly AK. Drug-induced liver injury: past, present and future. Pharmacogenomics, 2010,11: 607-611.
[6] Monshi MM, Faulkner L, Gibson A, et al. Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology. 2013,57:727-739.
[7] 周璐,王邦茂. 药物性肝损伤的免疫学研究进展. 胃肠病学,2014,19:641-643
[8] 于乐成,陈成伟. ACG特异质性药物性肝损伤临床诊治指南解读. 肝脏,2014,19:570-574.
[9] 任东东,邓存良. 药物性肝损伤的研究进展. 西南军医,2014,16:670-672.
[10] 中华医学会消化病学分会肝胆疾病协作组. 急性药物性肝损伤诊治建议(草案) .中华消化杂志, 2007,27:765-767.
[11] 中华医学会结核病学分会,《中华结核和呼吸杂志》编辑委员会.抗结核药所致药物性肝损伤诊断与处理专家建议. 中华结核和呼吸杂志,2013,36:732-736. |
